Jim Wu, PhD
Founder, Chairman and CEO

Dr. Jim Wu is Founder, Chairman and CEO of Ark Biopharmaceutical. He has over 25 years of experience in pharmaceutical research and development. Prior to founding the company, Dr. Wu served as a senior director of Roche R&D Center (China) Ltd., where he participated in multiple drug discovery programs in virology, oncology, and metabolic diseases. Dr. Wu is a prolific scientist with over 65 research papers published in international peer reviewed journals and is a co-inventor of ziresovir. 


Dr. Wu obtained his PhD from Brown University and his bachelor's degree from University of Science and Technology of China. He was a post-doctoral fellow at Harvard Medical School and formerly served on the editorial board of Antimicrobial Agents and Chemotherapy, one of the major anti-infectious disease publications.

Haiqing Yuan, PhD
COO

Dr. Haiqing Yuan is Chief Operating Officer of Ark Biopharmaceutical. Dr. Yuan has nearly 20 years of pre-clinical drug development and management experience in multinational pharmaceutical companies. Prior to joining Ark Biopharmaceutical, Dr. Yuan was a senior director at the international drug service unit of WuXi AppTec and, before then, a research investigator at Allergan, where he led multiple drug discovery programs. Dr.Yuan is an inventor with over 30 patents and a prolific author of papers and books.


He obtained his PhD from Virginia Polytechnic Institute and State University and his bachelor's degree from Fudan University. Dr. Yuan performed post-doctoral research at University of Notre Dame and Walther Cancer Institute.

Ki Rito, M.D. PhD
CMO

Dr. Ki Rito is Chief Medical Officer of Ark Biopharmaceutical. Dr. Rito received her medical training from China Medical University. She then served as a nephrologist and taught as a lecturer in medical school for 7 years. Subsequently, she obtained her PhD from the University of Tokyo, where she also performed post-doctoral research. Dr. Rito started her pharmaceutical industry career in Japan and worked at RIKEN Institute, Janssen, AstraZeneca, and Amgen, serving as a medical director and various medical & clinical leadership positions in which she played a key role in drug development in the areas of respiratory diseases, viral infection, autoimmune & inflammatory disease, and hematological oncology. Prior to joining Ark Biopharmaceutical, she held a leadership role in immunology at Harbour BioMed in charge of clinical development strategy of innovative medicines.

Junming Yie, PhD
CSO

Dr. Junming Yie is Chief Scientific Officer of Ark Biopharmaceutical. Dr. Yie has over 21 years of research experience working at Pfizer, Amgen, and Merck in USA, most recently as a group lead in biologicals process development and managed program in late-stage clinical development. He contributed to programs in different disease areas of metabolism, oncology, and immunology, and successfully initiated and led multiple projects from concept to clinical development. Dr. Yie has extensive experience in biologicals and small molecule drug discovery, CMC, analytical, and research team management. He published high impact research papers in Nature, Science, Cell, Science Translational Medicine, and more. Dr. Yie obtained his PhD with distinction in Biochemistry and Molecular Biophysics from Columbia University College of Physician and Surgeons and bachelor’s degree from University of Science and Technology of China. He then completed post-doctoral training at Dana-Farber Cancer Institute of Harvard Medical School. Dr. Yie also obtained MBA degree from UCLA Anderson School of Management.

Amos Chang
CCO

Amos Chang is Chief Commercial Officer of Ark Biopharmaceutical. Amos obtained his bachelor and master degrees from National Taiwan University major in agricultural Chemistry /Microbiology. He also received MBA degree from IESE Business School in Spain. Before joining ArkBio, Amos worked 8 years for GSK in China and UK, heading new product global and China launch for respiratory products in COPD and Asthma, and also in charge of sales and marketing for nebulization in the respiratory BU. After GSK, Amos took the role of GM with Joincare Pharmaceutical, overseeing commercialization of inhalation medicines, and successfully launched 2 new products in China. Between 2020 and 2022, Amos worked at Chiesi China as BU Head of primary care, in which he drove significant business growth and developed business strategy for COPD new product launch and NRDL inclusion. Amos Chang has extensive experience with new product launch, market access, alliance management, marketing and business operation, as well as having a rich knowledge in pediatric and respiratory therapeutic areas.

  • Home
  • Tel
  • Top